OptiNose Stock Forecast, Price & News

OptiNose's stock was trading at $5.06 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, OPTN shares have decreased by 23.3% and is now trading at $3.88.
View which stocks have been most impacted by COVID-19.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OptiNose in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for OptiNose.

OptiNose is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for OptiNose.

OptiNose Inc (NASDAQ:OPTN) issued its earnings results on Tuesday, August, 4th. The company reported ($0.56) earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.56). OptiNose had a negative return on equity of 282.14% and a negative net margin of 265.88%.
View OptiNose's earnings history.

4 Wall Street analysts have issued twelve-month target prices for OptiNose's shares. Their forecasts range from $17.00 to $25.00. On average, they expect OptiNose's stock price to reach $20.50 in the next year. This suggests a possible upside of 428.4% from the stock's current price.
View analysts' price targets for OptiNose.

OptiNose saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 7,640,000 shares, an increase of 15.1% from the August 15th total of 6,640,000 shares. Based on an average daily volume of 673,200 shares, the short-interest ratio is presently 11.3 days. Approximately 25.1% of the company's stock are sold short.
View OptiNose's Short Interest.

Some companies that are related to OptiNose include Phibro Animal Health (PAHC), Endo International (ENDP), RAPT Therapeutics (RAPT), VBI Vaccines (VBIV), Provention Bio (PRVB), Frequency Therapeutics (FREQ), Emisphere Technologies (EMIS), Kadmon (KDMN), Spectrum Pharmaceuticals (SPPI), Cara Therapeutics (CARA), ImmunoGen (IMGN), Northwest Biotherapeutics (NWBO), DiaMedica Therapeutics (DMCAF), Collegium Pharmaceutical (COLL) and ORIC Pharmaceuticals (ORIC).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other OptiNose investors own include Proteostasis Therapeutics (PTI), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Idera Pharmaceuticals (IDRA), Matinas BioPharma (MTNB), Dynavax Technologies (DVAX), Paratek Pharmaceuticals (PRTK), SCYNEXIS (SCYX), Selecta Biosciences (SELB) and Flexion Therapeutics (FLXN).

(OPTN) raised $101 million in an IPO on Friday, October 13th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, Piper Jaffray, BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO.

OptiNose trades on the NASDAQ under the ticker symbol "OPTN."

OptiNose's stock is owned by many different institutional and retail investors. Top institutional shareholders include Thrivent Financial for Lutherans (3.71%), Wasatch Advisors Inc. (2.02%), Paradigm Capital Management Inc. NY (1.62%), Nuveen Asset Management LLC (0.47%), Hudson Bay Capital Management LP (0.43%) and Charles Schwab Investment Management Inc. (0.39%). Company insiders that own OptiNose stock include Avista Capital Partners Ii Gp,, Joseph C Scodari, Keith A Goldan, Michael F Marino III, Peter K Miller, Ramy A Mahmoud and Thomas Edward Gibbs.
View institutional ownership trends for OptiNose.

OPTN stock was sold by a variety of institutional investors in the last quarter, including Kornitzer Capital Management Inc. KS, Wasatch Advisors Inc., Marshall Wace LLP, Hudson Bay Capital Management LP, Bank of New York Mellon Corp, UBS Group AG, and First Republic Investment Management Inc.. Company insiders that have sold OptiNose company stock in the last year include Avista Capital Partners Ii Gp,, Peter K Miller, and Ramy A Mahmoud.
View insider buying and selling activity for OptiNose.

OPTN stock was purchased by a variety of institutional investors in the last quarter, including Paradigm Capital Management Inc. NY, Nuveen Asset Management LLC, PDT Partners LLC, Bank of America Corp DE, California Public Employees Retirement System, SG Americas Securities LLC, Charles Schwab Investment Management Inc., and State of Wisconsin Investment Board. Company insiders that have bought OptiNose stock in the last two years include Joseph C Scodari, Keith A Goldan, Michael F Marino III, and Peter K Miller.
View insider buying and selling activity for OptiNose.

Shares of OPTN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of OPTN stock can currently be purchased for approximately $3.88.

OptiNose has a market capitalization of $178.45 million and generates $34.63 million in revenue each year. The company earns $-110,050,000.00 in net income (profit) each year or ($2.63) on an earnings per share basis. OptiNose employs 221 workers across the globe.

The official website for OptiNose is www.optinose.com.

OptiNose's mailing address is 1020 STONY HILL ROAD SUITE 300, YARDLEY PA, 19067. The company can be reached via phone at 267-364-3500 or via email at [email protected]